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Inthepastfewyearstheunderstandingoftherenin-angiotensinsystem(RAS)hasimproved,helpingtobetterdeﬁnetheroleofthis
system in physiological conditions and in human diseases. Besides Angiotensin (Ang) II, the biological importance of other Ang
fragments was progressively evidenced. In this regard, Angiotensin- (Ang-) (1-7) was recognized as a biologically active product
of the RAS cascade with a speciﬁc receptor, the G-protein-coupled receptor Mas, and that is mainly formed by the action of the
angiotensin-converting enzyme (ACE) homolog enzyme, ACE2, which converts Ang II into Ang-(1-7). Taking into account the
biological eﬀects of these two mediators, Ang II and Ang-(1-7), the RAS can be envisioned as a dual function system in which
the vasoconstrictor/proliferative or vasodilator/antiproliferative actions are primarily driven by the balance between Ang II and
Ang-(1-7), respectively. In this paper, we will discuss our current understanding of the ACE2/Ang-(1-7)/Mas axis of the RAS in
renal physiology and in the pathogenesis of primary hypertension and chronic kidney disease.
1.Introduction
1.1. Historical Background of the ACE2/Ang-(1-7)/Mas Axis
of the RAS. In the past few years the understanding of
the renin-angiotensin system (RAS) has improved, helping
to better deﬁne the role of this system in physiological
conditions and in human diseases. Following the seminal
study of Schiavone and coworkers [1] demonstrating that
Angiotensin- (Ang-) (1-7) is a biologically active peptide of
the RAS, several reports have clearly shown that this hep-
tapeptide plays important functions in cardiovascular and
renal system [2, 3].
The identiﬁcation of the angiotensin-converting enzyme
(ACE) homologue, ACE2, as the main Ang-(1-7)-forming
enzyme was essential to establish a preferential enzymatic
pathway for the production of this angiotensin peptide [4,
5]. ACE2 can cleave Ang I to form Ang-(1-9) [4], which
is subsequently converted to Ang-(1-7) through ACE and
neutral-endopeptidase 24.11 (NEP) activity [6]. However,
the main substrate for ACE2 is Ang II, which is converted
into Ang-(1-7) [7]. Consequently, ACE2 plays a pivotal role
in the balance between both RAS mediators, Ang II and Ang-
(1-7), once this enzyme can convert Ang II, a vasoconstrictor
peptide, into Ang-(1-7), a vasodilator peptide. However, it
should be mentioned that, besides ACE2, other enzymes
might contribute to Ang-(1-7) formation such as prolylen-
dopeptidase (PEP), prolylcarboxypeptidase (PCP), and NEP
[8–10].
Further support for the relevance of Ang-(1-7) was
achievedwiththedescriptionoftheorphanreceptorMasasa
functionalligandsiteforthisangiotensin[11].Thisdiscovery
was a conﬁrmation of results previously obtained with the
Ang-(1-7) antagonists, suggesting that Ang-(1-7) exerted its
actions through a speciﬁc receptor, distinct from Ang II
receptors type 1 (AT1)a n dt y p e2( A T 2)[ 12, 13].
It is now conceived that the RAS axis formed by ACE2,
Ang-(1-7), and Mas is able to counter balance many of the
well-established actions of the ACE-Ang II-AT1 receptor axis
[2, 3, 14, 15]. Accordingly, the activation of the vasodilator/
antiproliferative axis might represent an endogenous pro-
tective mechanism against the deleterious eﬀects elicited by
the ACE-Ang II-AT1 receptor axis, especially in pathological2 International Journal of Hypertension
conditions [2, 3, 14]. However, the role of ACE2-Ang-(1-7)-
Masaxisappearstogofarbeyondacounterregulatoryaction.
This paper will brieﬂy highlight recent ﬁndings concern-
ing the renal eﬀects of the ACE2-Ang-(1-7)-Mas axis in renal
physiology and discuss its potential role in disease states.
1.2. The Role of ACE2/Ang-(1-7)/Mas Axis in Renal Physiol-
ogy. A growing body of evidence supports the relevance of
Ang-(1-7) for the regulation of renal function. Ang-(1-7) is
present in the kidney at concentrations that are comparable
to Ang II [8, 15]. The processing pathways for Ang-(1-7)
in the circulation and kidney appear to be distinct. In the
circulation, NEP is one of the major enzymes that produce
Ang-(1-7) from Ang I or Ang-(1-9) [8]. In the kidney,
NEP may contribute to both the synthesis as well as the
degradation of Ang-(1-7). This enzyme cleavesAng I to Ang-
(1-7) and also metabolizes the peptide at Tyr4-Ile5 bond to
form Ang-(1-4) and Ang-(5-7) [16, 17]. ACE2 seems to be
the primarily responsible for Ang-(1-7) synthesis in the renal
tissue [15].
It should be pointed that there are gender diﬀerences
in renal activity of ACE2 and in the mRNA expression for
this enzyme at renal tissue. In this regard, Ji and coworkers
showed that ovariectomy decreased ACE2 protein (30%)
and mRNA expression (36%) in renal wrap hypertension
in rats, while 17-beta-estradiol replacement prevented these
eﬀects[18].Inaddition,theinfusionofAng-(1-7)attenuated
renal injury which was exacerbated by ovariectomy in this
experimental model [18]. The authors concluded that 17-
beta-estradiol-mediated upregulation of renal ACE2 and the
consequent increased Ang-(1-7) production might protect
against hypertensive renal disease. More recently, Liu and
coworkers found that ACE2 activity was higher in the kidney
of male mice compared to the kidney of females [19]. These
authors believe that sex diﬀerences in renal ACE2 activity
in intact mice are due, at least in part, to the presence of
17-beta-estradiol in the ovarian hormone milieu and not to
the testicular milieu or to diﬀerences in sex chromosome
dosage (2X versus 1X; 0Y versus 1Y) [19]. Therefore, the
regulation of renal ACE2 by 17-beta-estradiol has particular
implications for women across their life span since this
hormone changes radically during puberty, pregnancy, and
menopause.
Ang-(1-7) is the main product obtained in preparations
of isolated proximal tubules and exists in urine at higher
concentrations than Ang II [17]. The heptapeptide is also
present in the distal convoluted tubules and collecting ducts
[20]. Chappell et al. [15] demonstrated that the distribution
of ACE2 within renal tubules is similar to that of Ang-(1-
7). This ﬁnding was a preliminary evidence for the direct
conversion of Ang II to Ang-(1-7) in the kidney. In keeping
with these observations, Ferrario et al. [21]s u p p o r t e da
role for ACE2 in Ang-(1-7) formation from Ang II in the
kidney of normotensive rats. This study showed an increased
ACE2 activity measured in renal tissue of rats given either
lisinopril or losartan [21]. These data further suggest that
increased levels of Ang-(1-7) in the urine of animals under
ACE inhibition or AT1 receptor blockade might reﬂect an
intrarenal formation of this heptapeptide [21].
Many studies have addressed the complexity of renal
actionsofAng-(1-7)[8,15,22–26].Diﬀerences between spe-
cies, local and systemic concentrations of Ang-(1-7), neph-
ron segment, level of RAS activation, and sodium and water
status can be responsible for discrepant results concerning
renal eﬀects of Ang-(1-7). A diuretic/natriuretic action of
Ang-(1-7) has been described in several in vitro [27–30]
and in vivo experimental models, mostly by inhibition of
sodium reabsorption at proximal tubule [28, 31, 32]. Ang-
(1-7) seems to be a potent inhibitor of Na-K-ATPase activity
in the renal cortex [33] and in isolated convoluted proximal
tubules [34]. In renal tubular epithelial cells, Ang-(1-7)
inhibited transcellular ﬂux of sodium, which was associated
with activation of phospholipase A2 [27]. In vitro studies also
indicated that Ang-(1-7) modulates the stimulatory eﬀect
of Ang II on the Na-ATPase activity in proximal tubule
through an A779-sensitive receptor. In this regard, B¨ urgelov´ a
et al. [34] showed that intrarenal administration of Ang-
(1-7) produced natriuresis and blocked the antinatriuretic
actions of Ang II.
On the other hand, our group and other investigators
have observed an antidiuretic/antinatriuretic eﬀect induced
by Ang-(1-7), especially in water-loaded animals [11, 22, 23,
32, 35–41]. Ang-(1-7) has a potent antidiuretic activity in
water-loaded rats [38, 39]a n dm i c e[ 35] probably mediated
by the receptor Mas [11]. In vitro, Ang-(1-7) increased
the water transport in the inner medullary collecting duct
through an interaction between receptor Mas and the vaso-
pressin type 2 receptor with subsequent adenylate cyclase
activation [41]. These data were in accordance with the renal
eﬀects produced by the selective Ang-(1-7) receptor Mas
antagonists, the compounds A-779 [12, 38–41]a n dDP r o 7-
Ang-(1-7) [42]. The administration of these antagonists
exerts a diuretic eﬀect associated with an increase in
glomerular ﬁltration rate and in water excretion [38–42].
These ﬁndings suggest that endogenous Ang-(1-7) takes
part in the regulation of glomerular ﬁltration and of water
handling at renal level.
The physiological relevance of Ang-(1-7) was further
corroborated by the demonstration that Ang-(1-7) is an
endogenous ligand for the G-protein-coupled receptor Mas
in the kidney [11]. Immunocytochemical data reveal a
similar distribution for Ang-(1-7), ACE2, and the Mas
receptor within the tubular epithelium of the kidney [15].
Experimental data obtained with receptor Mas agonists and
antagonists help understanding the role of this receptor in
renal physiology. In water-loaded C57BL/6 mice, the admin-
istration of the oral agonist of receptor Mas, the compound
AVE 0991, produced a signiﬁcant reduction in urinary vol-
ume, associated with an increase in urinary osmolality [35].
The receptor Mas antagonist, A-779, completely blocked the
antidiuretic eﬀect of AVE 0991 [35]. As observed previously
for Ang-(1-7) [11], the antidiuretic eﬀect of AVE 0991 after
water load was blunted in mice with genetic deletion of
receptor Mas [35]. In vitro receptor autoradiography in
C57BL/6 mice showed that the speciﬁc binding of 125I-Ang-
(1-7) to mouse kidney slices was displaced by AVE 0991,
whereas no eﬀects were observed in the binding of 125I-Ang
II or 125I-Ang IV [35]. More recently, these ﬁndings wereInternational Journal of Hypertension 3
further corroborated taking advantage of a novel transgenic
rat model, TGR(A1-7)3292, that expresses an Ang-(1-7)-
producing fusion protein which produces chronic elevation
in Ang-(1-7) plasma concentration [43]. In this study, trans-
genic rats presented a signiﬁcant reduction of basal urinary
volumeandoffreewaterclearance,withoutchangingplasma
levels of vasopressin and the mRNA expression of Mas and
vasopressin type 2 receptors in renal tissue [43].
Beside important tubular actions, Ang-(1-7) also con-
tributes to renal hemodynamic regulation. The ability of
the kidney to generate high intratubular and interstitial
concentrations of Ang II and Ang-(1-7) allows the kidney
to regulate intrarenal levels of these angiotensins in accord
with the homeostatic needs for the regulation of renal
hemodynamics, tubular reabsorption, and sodium balance.
When the RAS is inappropriately stimulated, high intrarenal
Ang II levels, acting on AT1 receptors, can lead to both
systemic and glomerular capillary hypertension, which can
induce hemodynamic injury to the vascular endothelium
and glomerulus [44, 45]. In addition, direct proﬁbrotic and
proinﬂammatory actions of Ang II may also promote kidney
damage [44–46]. On the other hand, Ren et al. [47]r e p o r t e d
that Ang-(1-7)-induced dilatation of pre-constricted renal
aﬀerent arterioles in rabbits and Sampaio et al. [48] showed
that an infusion of low concentrations of Ang-(1-7) in-
creased renal blood ﬂow in rats. Ang-(1-7) also attenuated
the eﬀect of Ang-II-induced pressor responses and Ang-II-
enhanced noradrenaline release to renal nerve stimulation in
rat isolated kidney [49]. These results opened the possibility
that Ang-(1-7) can also act as a physiological regulator of
intraglomerular pressure, probably opposing the hyperten-
sive and ﬁbrogenic eﬀects of Ang II.
2.The Role of ACE2/Ang-(1-7)/MasAxis
inRenalDiseases
2.1. Current Experimental Evidence. Experimental studies
have also indicated a role for the Ang-(1-7)-Mas interaction
in the regulation of matrix proteins deposition in the heart
and liver [50, 51]. Our group has shown ﬁbronectin and
collagen III deposition in the kidney of mice with genetic
deletion of receptor Mas, suggesting that these genetic
modiﬁedanimalsexhibitaphenotypepredispositiontorenal
ﬁbrosis [52]. Accordingly, at initial stages of collagen deposi-
tion and renal ﬁbrosis, type III collagen appears in greater
amounts than do type I. As renal ﬁbrosis progresses, there is
a proportional decrease in type III collagen, and tubuloin-
terstitial ﬁbroblasts secrete collagen types I, III, IV, and V
in response to TGF-beta, epidermal growth factor, and
interleukin-2 [53, 54]. More recently, Zhang et al. demon-
strated that infusion of angiotensin-(1-7) reduces glomeru-
losclerosis through counteracting angiotensin II in experi-
mental glomerulonephritis [55], suggesting that Ang-(1-7)
is also relevant for modulating renal ﬁbrosis in disease states.
Although a protective role for Ang-(1-7) in renal ﬁbrosis
remains speculative, our ﬁndings in animals with genetic
deletion of receptor Mas support this hypothesis [52]. In ad-
dition, many studies have shown that Ang-(1-7) exerts in-
hibitory eﬀects on vascular and cellular growth mechanisms.
The molecular mechanisms for the antiproliferative action
of Ang-(1-7) include the stimulation of prostaglandin and
cAMPproductionaswelltheinhibitionofmitogen-activated
protein (MAP) kinases [56]. The antiproliferative eﬀects
of Ang-(1-7) in vascular smooth muscle cells [57], liver
tissue [51], and cardiomyocytes [58] seem to be mediated
by receptor Mas. Moreover, Mas-deﬁcient mice exhibited an
impairment of heart function associated with changes in
collagen expression toward a proﬁbrotic proﬁle [50]. Gal-
lagherandTallant[59]alsoreportedtheinhibitionofhuman
lung cell growth by Ang-(1-7) through a reduction in the
serum-stimulated phosphorylation of extracellular signal-
regulated kinase (ERK) 1 and ERK2. As the ERK cascade
is activated in response to diﬀerent stimuli, such as growth
factors, cytokines, or DNA-damaging agents, the stimulation
of the ACE2-Ang-(1-7)-Mas axis could be eﬀective in halting
glomerulosclerosis. Su et al. [60] have reported that Ang-(1-
7) inhibits Ang II-stimulated MAP kinases phosphorylation
in proximal tubular cells. Thus, the generation of Ang-(1-7)
by proximal tubular ACE2 could counteract the proliferative
eﬀects of locally produced Ang II [60].
In keeping with this possibility, recent studies suggested a
protective role for ACE2 in the kidney. Kidney diseases have
been associated with a reduction in renal ACE2 expression,
possibly facilitating the damaging eﬀects of Ang II. Acquired
or genetic ACE2 deﬁciency also appears to exacerbate renal
damage and albuminuria in experimental models, support-
ing this hypothesis [61–67]. In addition, chronic blockade
of ACE2 with the enzyme inhibitor MLN-4760 in control
or diabetic mice produced albuminuria and matrix protein
deposition [65]. More recently, Dilauro et al. [66] showed
that ACE2 is downregulated in the renal cortex of mice that
underwent subtotal nephrectomy. The reduction of renal
ACE2 in nephrectomized animals led to proteinuria via an
AT1 receptor dependent mechanism [66]. Accordingly, the
renal expression of ACE2 was also reduced in an experimen-
talmodelofrenalischemia/reperfusion[67].Takentogether,
these ﬁndings suggest that decreased ACE2 activity may be
involved in the pathogenesis of kidney disease, possibly by
disrupting themetabolismofangiotensinpeptides[68].Tak-
ing into account the enzymatic properties of the two ACEs
and of the two main mediators Ang II and Ang-(1-7), the
RAScanbeenvisionedasadualfunctionsysteminwhichthe
vasoconstrictor/proliferative or vasodilator/antiproliferative
actions are primarily driven by the ACE–ACE2 balance.
Accordingly, an increased ACE/ACE2 activity ratio will lead
to increased Ang II generation and increased catabolism of
Ang-(1-7), favoring vasoconstriction, while a decreased ratio
willdecreaseAngIIandincreaseAng-(1-7)levels,facilitating
vasodilatation [68–70].
On the other hand, some studies pointed to a deleterious
role for Ang-(1-7) at renal system. For instance, the study
of Esteban and coworkers using mice with genetic deletion
of receptor Mas showed very discrepant results in relation to
renal function when compared to our ﬁndings [71]. While
our research group [52] showed that the genetic deletion
of receptor Mas in C57Bl/6 mice led to glomerular hyper-
ﬁltration, proteinuria and renal ﬁbrosis, Esteban et al. [28]
reported that renal deﬁciency of Mas diminished renal4 International Journal of Hypertension
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Figure 1: Proposed mechanisms for the role of ACE-Ang II-AT1 receptor axis in excess of ACE2-Ang-(1-7)-Mas receptor axis at renal level.
damageinunilateralureteralobstructionandinischemia/re-
perfusion injury, and that the infusion of Ang-(1-7) to wild-
type mice elicited an inﬂammatory response. Furthermore,
animal models of renal diseases have also showed discrepant
ﬁndings. Zhang et al. [55] showed that a 5-day infusion of
Ang-(1-7) improved glomerulosclerosis in a rat model of
thy-1-induced glomerulonephritis, whereas Velkoska et al.
[72] veriﬁed that a 10-day infusion of the same concentra-
tion of Ang-(1-7) in rats with subtotal nephrectomy was
associated with deleterious eﬀects on blood pressure and the
heart, with increase in cardiac ACE, and decrease in cardiac
ACE2 activity. Although these ﬁndings are conﬂicting, cell-
speciﬁc signaling pathways associated with Ang-(1-7) in the
kidney could play a role in the variable response. In this
regard, in the proximal tubule Ang-(1-7) displays growth
inhibitory properties and antagonizes the eﬀects of Ang II
[60], whereas in mesangial cells, it appears to stimulate cell
growth pathways [73]. In addition, the vascular and tubular
eﬀects of Ang-(1-7) in the kidney appear to be importantly
inﬂuenced by experimental conditions and the level of RAS
activation [74].
2.2. Current Clinical Evidence. Agonists and antagonists
of the Ang-(1-7)-Mas axis probably possess a therapeutic
potential for the modulation of sodium and water excretion
in many physiologic and pathologic renal conditions, such
as arterial hypertension, nephrogenic diabetes insipidus,
glomerular diseases, chronic kidney disease (CKD), and dia-
betic nephropathy (see [68–70], for review). Ang-(1-7) can
bemeasuredinplasmaandurinesamplescollectedinhealthy
subjects and in patients with diverse clinical conditions (see
[68–70], for review). Changes in blood pressure, in blood
volume, in sodium intake and in renal function were able
to modify the levels of Ang-(1-7) measured in plasma, renal
tissue, and urine [75–81]. In addition, the concentration of
the heptapeptide may diﬀer in plasma and urine samples
of the same subject. Accordingly, Ferrario and coworkers
have reported that Ang-(1-7) is excreted in the urine of
normal healthy adult volunteers in amounts 2.5-fold higher
than those measured in plasma [82]. In the same study,
it was also observed that untreated adults with primary
hypertension exhibited a lower urinary excretion of Ang-(1-
7) than normotensive controls and urinary concentrations
of Ang-(1-7) were inversely correlated with blood pressure
[82].
In pediatric patients, Sim˜ o e seS i l v aa n dc o w o r k e r sh a v e
reported signiﬁcant diﬀerences among circulating Ang II
and Ang-(1-7) levels in renovascular disease and in primary
hypertension [83]. Children with renovascular hypertension
had plasma levels of Ang II higher than of Ang-(1-7) and
the successful correction of unilateral renal artery stenosis
producedareturnofcirculatingangiotensinstolevelssimilar
to those in healthy subjects. In contrast, patients with
primary hypertension had signiﬁcant elevation of circulating
Ang-(1-7), while the levels of Ang I and Ang II were within
the same range as in healthy subjects. In addition, the
achievement of blood pressure control with calcium channel
blockers did not change plasma concentration of Ang-(1-
7) and Ang II. The physiopathological meaning of increased
levels of only Ang-(1-7) in pediatric primary hypertension is
still unknown and raises the question whether this elevation
is a compensatory mechanism that opposes deleterious renal
and cardiovascular eﬀects of Ang II or whether, at supra
physiological concentrations, Ang-(1-7) could act as another
RAS mediator of renal dysfunction.
In addition, Sim˜ oes e Silva et al. have demonstrated a
signiﬁcant increase in plasma Ang-(1-7) and Ang II levels
among hypertensive children with CKD stage III when
comparedtonormotensiveCKDpatientswiththesamestage
ofrenaldysfunction[76].Whilethepresenceofhypertension
aﬀected plasma concentration of both peptides, the progres-
sion to end stage renal disease was accompanied by more
pronounced elevation only in Ang-(1-7) levels. Ang II levels
were similarly elevated despite the level of renal dysfunction.
Taken together, these data support a preferential production
of Ang-(1-7) in end stage renal disease [76]. Future studiesInternational Journal of Hypertension 5
are needed to elucidate the physiopathological role of this
heptapeptide in human CKD.
Another important aspect to be considered is the ele-
vation of plasma Ang-(1-7) during chronic RAS inhibition
[76–79]. The renoprotective actions of ACE inhibitors and
AT1 receptor blockers clearly involve multiple pathways
including antiproliferative and antiﬁbrogenic eﬀects [78, 80,
81]. In particular, an altered balance between Ang II and
Ang-(1-7) might be related to the mechanism of action
of ACE inhibition and AT1 receptor blockade. Studying
healthy subjects, Kocks et al. [79] showed that, during ACE
inhibition, the administration of a low sodium diet did
not aﬀect plasma levels of Ang II but induced a signiﬁcant
elevation in Ang-(1-7) concentration. Consequently, the
combination of ACE inhibition and a low sodium diet
appeared to shift the balance between Ang-(1-7) and Ang
II towards Ang-(1-7), which in turn might contribute to the
therapeutic beneﬁts of ACE inhibition [79].
3. Concluding Remarks
The current evidence supports the existence of a counterreg-
ulatory axis within the RAS formed mainly by the ACE2-
Ang-(1-7)-receptor Mas axis. The primary function of this
axis is to oppose the eﬀects of the major component of
the RAS, Ang II. Experimental and clinical studies have
demonstrated a role for the ACE2/Ang-(1-7)/Mas axis in the
regulation of renal function, in arterial hypertension, and
in the progression of CKD. Figure 1 shows the proposed
mechanisms for the role of ACE-Ang II-AT1 receptor axis
in excess of ACE2-Ang-(1-7)-Mas receptor axis at renal
level. Therefore, the disproportion between both RAS axes
might represent an important pathway for CKD progression
(Figure 1). Further research on the contribution of the
ACE2/Ang-(1-7)/Mas axis to renal pathophysiology should
lead to the development of new pharmacologic approaches
resulting in the design of molecular or genetic means to
increase the expression of ACE2, allow for increased tissue
levels of Ang-(1-7), or both.
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